CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Nov 1, 2019

Keywords

ClinConnect Summary

The CARMA study is a clinical trial focusing on Canadian patients with cancer who have unusual changes in their tumor DNA. These changes can affect how the cancer behaves and how it responds to specific treatments. The study aims to collect information about different types of cancer with rare genetic alterations, like those found in genes such as ALK, EGFR, and KRAS. Researchers hope to learn more about how these tumors develop, how patients respond to various therapies, and any side effects they experience from treatments.

To participate in the study, individuals must be at least 18 years old, diagnosed with a malignant tumor that has been tested for these rare genetic changes, and currently receiving or planning to receive cancer care in Canada. Participants will have their treatment outcomes monitored, and their experiences will be documented to help improve understanding of these rare cancer types. It’s important for potential participants to know that the study is currently recruiting and aims to contribute valuable knowledge to cancer treatment and care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients ≥ 18 years at cancer diagnosis
• • Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations
• • Accessible/available molecular testing reports/documentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction \[PCR\] based next generation sequencing \[NGS\], immunohistochemistry \[IHC\], fluorescence in situ hybridization \[FISH\], liquid biopsy)
• • Canadian resident received follow-up for cancer care in Canada or is currently receiving/planning follow-up for cancer care to occur in Canada at time of enrollment
• Exclusion Criteria:
• • Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent